M. Schütte

Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.

Norbert Marschner, R. Kreienberg, R. Souchon et al. · PubMed · 1994 · 50 citations

Medicine, Oncology, Pharmacology +16

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial

Gilles Romieu, Michael Clemens, Rolf Mahlberg et al. · Critical Reviews in Oncology/Hematology · 2007 · 37 citations

Medicine, Oncology, Pharmacology +9

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

Georgia Schilling, M. Bruweleit, Nadia Harbeck et al. · Investigational New Drugs · 2008 · 17 citations

Medicine, Oncology, Pharmacology +17

Health Applications for Corporate Health Management

Guido Steigner, Charles R. Doarn, M. Schütte et al. · Telemedicine Journal and e-Health · 2016 · 17 citations

Public Health, Health Informatics, Health Management +6

Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC)

Maike de Wit, Nadia Harbeck, Christoph Thomssen et al. · Journal of Clinical Oncology · 2004 · 12 citations

Medicine, Oncology, Pharmacology +17